T. Rowe Price Investment Management
ADPT icon

T. Rowe Price Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

T. Rowe Price Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8M Buy
919,278
+916,150
+29,289% +$14.6M 0.01% 521
2025
Q4 		$51K Buy
+3,128
New +$51K ﹤0.01% 666
2023
Q4 		– Sell
-1,070,588
Closed -$5.83M – 597
2023
Q3 		$5.83M Hold
1,070,588
– – ﹤0.01% 538
2023
Q2 		$7.18M Sell
1,070,588
-9,940
-0.9% -$73.9K ﹤0.01% 524
2023
Q1 		$9.54M Buy
1,080,528
+412,326
+62% +$3.64M 0.01% 517
2022
Q4 		$5.11M Sell
668,202
-3,600
-0.5% -$28K ﹤0.01% 522
2022
Q3 		$4.78M Buy
+671,802
New +$6.33M ﹤0.01% 527

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Investment Management's ADPT Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Adaptive Biotechnologies (ADPT) stake by 29,289% in Q1 2026, buying an estimated $14.6M and bringing the position to 919,278 shares worth $12.8M. The position accounts for 0.01% of the portfolio, ranked #521.

T. Rowe Price Investment Management first reported a position in ADPT in Q3 2022 and has held it in 7 quarters since. 296 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • T. Rowe Price Investment Management held 919,278 shares of Adaptive Biotechnologies worth $12.8M as of Q1 2026.
  • T. Rowe Price Investment Management bought 916,150 Adaptive Biotechnologies shares in Q1 2026, an estimated $14.6M.
  • Adaptive Biotechnologies made up 0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #521 holding.
  • T. Rowe Price Investment Management first reported a position in Adaptive Biotechnologies in Q3 2022 and has held it in 7 quarters since.
  • 296 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.